Assessment of mpox awareness, attitudes, and vaccination intent among the United States public following an outbreak of mpox clade Ib in Africa.

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-04-24 DOI:10.1016/j.vaccine.2025.127141

Hannah Melchinger , Maya Khemsara , Noureen Ahmed , Sameer M. Belgaumi , Krutika Kuppalli , Saad B. Omer , Amyn A. Malik

{"title":"Assessment of mpox awareness, attitudes, and vaccination intent among the United States public following an outbreak of mpox clade Ib in Africa.","authors":"Hannah Melchinger , Maya Khemsara , Noureen Ahmed , Sameer M. Belgaumi , Krutika Kuppalli , Saad B. Omer , Amyn A. Malik","doi":"10.1016/j.vaccine.2025.127141","DOIUrl":null,"url":null,"abstract":"<div><div>During the global outbreak of Clade IIb mpox (formerly known as monkeypox) in 2022, a survey of the US adult population (18+) found that knowledge of mpox and intention to vaccinate against it were low. Given the ongoing surge of Clade Ib in Africa, and recent reports of cases outside of Africa and in the US, we conducted a similar survey to assess whether US adult knowledge, attitudes, and practices towards mpox have changed since 2022. The survey, hosted by online survey company CloudResearch, asked questions about mpox awareness, risk perception, intention to vaccinate, and trusted sources of information. We found that 58% (95% CI 52–62) of US adults would be willing to receive the mpox vaccine if recommended by their doctor or health authority, a 12% increase from our 2022 results. Respondents from Health and Humans Services (HHS) Region 1 (CT, ME, MA, NH, RI, VT) were least likely to receive the vaccine, even if recommended to do so. Self-reported knowledge of mpox (40%), as well as perceived self-efficacy (55%) and mean risk perception (3.2) have also increased since the 2022 survey. Healthcare professionals remain the most trusted source of information (73%), and trust in the US government to provide accurate information has increased (58%). These results highlight the need for ongoing education among US adults to improve awarness of and vaccination intention for the mpox vaccine. The consistently high degrees of trust placed in healthcare professionals and officials should guide future communications about mpox and other infectious diseases, and reinforce the importance of leveraging trusted sources to share essential public health information.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127141"},"PeriodicalIF":4.5000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25004384","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

During the global outbreak of Clade IIb mpox (formerly known as monkeypox) in 2022, a survey of the US adult population (18+) found that knowledge of mpox and intention to vaccinate against it were low. Given the ongoing surge of Clade Ib in Africa, and recent reports of cases outside of Africa and in the US, we conducted a similar survey to assess whether US adult knowledge, attitudes, and practices towards mpox have changed since 2022. The survey, hosted by online survey company CloudResearch, asked questions about mpox awareness, risk perception, intention to vaccinate, and trusted sources of information. We found that 58% (95% CI 52–62) of US adults would be willing to receive the mpox vaccine if recommended by their doctor or health authority, a 12% increase from our 2022 results. Respondents from Health and Humans Services (HHS) Region 1 (CT, ME, MA, NH, RI, VT) were least likely to receive the vaccine, even if recommended to do so. Self-reported knowledge of mpox (40%), as well as perceived self-efficacy (55%) and mean risk perception (3.2) have also increased since the 2022 survey. Healthcare professionals remain the most trusted source of information (73%), and trust in the US government to provide accurate information has increased (58%). These results highlight the need for ongoing education among US adults to improve awarness of and vaccination intention for the mpox vaccine. The consistently high degrees of trust placed in healthcare professionals and officials should guide future communications about mpox and other infectious diseases, and reinforce the importance of leveraging trusted sources to share essential public health information.

查看原文本刊更多论文

评估非洲mpox分支b暴发后美国公众对mpox的认识、态度和接种意图。

在2022年全球爆发ii支m痘（以前称为猴痘）期间，对美国成年人口（18岁以上）的一项调查发现，对m痘的了解和接种疫苗的意愿很低。鉴于非洲mpox的持续激增，以及最近非洲以外和美国的病例报告，我们进行了类似的调查，以评估自2022年以来美国成人对mpox的知识、态度和做法是否发生了变化。该调查由在线调查公司CloudResearch主持，询问了有关m痘意识、风险认知、接种疫苗的意图和可信赖的信息来源的问题。我们发现，如果医生或卫生当局建议，58% （95% CI 52-62）的美国成年人愿意接种m痘疫苗，比我们2022年的结果增加了12%。来自卫生与人类服务部（HHS） 1区（CT、ME、MA、NH、RI、VT）的应答者最不可能接种疫苗，即使被建议这样做。自2022年调查以来，自我报告的m痘知识（40%）、自我效能感（55%）和平均风险感知（3.2）也有所增加。医疗保健专业人员仍然是最值得信赖的信息来源（73%），对美国政府提供准确信息的信任有所增加（58%）。这些结果强调需要在美国成年人中进行持续教育，以提高对m痘疫苗的认识和接种意愿。对保健专业人员和官员的一贯高度信任应指导今后关于麻疹和其他传染病的交流，并强调利用可靠来源分享基本公共卫生信息的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.